Regulated intramembrane proteolysis of the TGFβ type I receptor conveys oncogenic signals

Future Oncology

Volumn 10, Issue 11, 2014, Pages 1853-1861

  Gudey, Shyam Kumar ^a   Wallenius, Anders ^a   Landström, Marene ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cancer; Nucleus tgf ; Proteolysis; Receptors; Signal transduction

Indexed keywords

CELL NUCLEUS RECEPTOR; CELL SURFACE RECEPTOR; GROWTH FACTOR; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; CELL RECEPTOR; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER CELL; CARCINOGENESIS; GENE TRANSLOCATION; INTRACELLULAR SIGNALING; NEOPLASM; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR PROMOTION; CELL MEMBRANE; CELL NUCLEUS; CELL TRANSFORMATION; DISEASE COURSE; HUMAN; METABOLISM; PATHOLOGY;

CELL MEMBRANE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905901458     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/FON.14.45     Document Type: Article

References (79)

1. Massague J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 (2012).
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 139(5), 871-890 (2009).
3. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21(2), 166-176 (2009).
4. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 10(6), 415-424 (2010).
5. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res. 347(1), 11-20 (2012).
6. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Develop. Cell 16(3), 329-343 (2009).
7. ten Dijke P, Miyazono K, Heldin CH. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr. Opin. Cell Biol. 8(2), 139-145 (1996).
8. Groppe J, Hinck CS, Samavarchi-Tehrani P et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29(2), 157-168 (2008).
9. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 370(6488), 341-347 (1994).
10. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin CH. Formation of heterooligomeric complexes of type I and type II receptors for transforming growth factor-beta. J. Biol. Chem. 269(31), 20172-20178 (1994).
11. Yamaguchi K, Shirakabe K, Shibuya H et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270(5244), 2008-2011 (1995).
12. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Develop. 12(1), 22-29 (2002).
13. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 19(1), 128-139 (2009).
14. Sorrentino A, Thakur N, Grimsby S et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinaseindependent manner. Nat. Cell Biol. 10(10), 1199-1207 (2008).
15. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275(47), 36803-36810 (2000).
16. Zhang L, Zhou F, Ten Dijke P. Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem. Sci. 38(12), 612-620 (2013).
17. Hamidi A, von Bulow V, Hamidi R et al. Polyubiquitination of transforming growth factor beta (TGFbeta)-associated kinase 1 mediates nuclear factor-kappaB activation in response to different inflammatory stimuli. J. Biol. Chem. 287(1), 123-133 (2012).
18. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 31(6), 918-924 (2008).
19. Gough NR. Kinase-independent signaling from TGF-β receptors to TAK1. Sci. Signal. 1(40), ec348 (2008).
20. Starczynowski DT, Lockwood WW, Delehouzee S et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J. Clin. Invest. 121(10), 4095-4105 (2011).
21. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett. 586(14), 1959-1970 (2012).
22. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nature reviews. Drug Discov. 11(10), 790-811 (2012).
23. Haass C, Schlossmacher MG, Hung AY et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359(6393), 322-325 (1992).
24. Shoji M, Golde TE, Ghiso J et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258(5079), 126-129 (1992).
25. De Strooper B, Annaert W, Cupers P et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398(6727), 518-522 (1999).
26. Hayashida K, Bartlett AH, Chen Y, Park PW. Molecular and cellular mechanisms of ectodomain shedding. Anat. Rec. 293(6), 925-937 (2010).
27. Khandelwal A, Chandu D, Roe CM, Kopan R, Quatrano RS. Moonlighting activity of presenilin in plants is independent of gamma-secretase and evolutionarily conserved. Proc. Natl Acad. Sci. USA 104(33), 13337-13342 (2007).
28. McMains VC, Myre M, Kreppel L, Kimmel AR. Dictyostelium possesses highly diverged presenilin/gamma-secretase that regulates growth and cell-fate specification and can accurately process human APP: a system for functional studies of the presenilin/gamma-secretase complex. Dis. Model. Mech. 3(9-10), 581-594 (2010).
29. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100(4), 391-398 (2000).
30. Marambaud P, Wen PH, Dutt A et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114(5), 635-645 (2003).
31. Reiss K, Maretzky T, Ludwig A et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 24(4), 742-752 (2005).
32. Lee JR, Urban S, Garvey CF, Freeman M. Regulated intracellular ligand transport and proteolysis control EGF signal activation in Drosophila. Cell 107(2), 161-171 (2001).
33. Urban S, Lee JR, Freeman M. Drosophila rhomboid-1 defines a family of putative intramembrane serine proteases. Cell 107(2), 173-182 (2001).
34. Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. Semin. Cancer Biol. 14(5), 320-328 (2004).
35. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development 138(17), 3593-3612 (2011).
36. Rajagopal C, Mains RE, Eipper BA. Signaling from the secretory granule to the nucleus. Crit. Rev. Biochem. Mol. Biol. 47(4), 391-406 (2012).
37. Blobel CP, Carpenter G, Freeman M. The role of protease activity in ErbB biology. Exp. Cell Res. 315(4), 671-682 (2009).
38. Carpenter G, Liao HJ. Receptor tyrosine kinases in the nucleus. Cold Spring Harbor Persp. Biol. 5(10), a008979 (2013).
39. Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology 23, 194-204 (2008).
40. Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J. Neurochem. 93(4), 769-792 (2005).
41. De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Ann. Rev. Cell Develop. Biol. 26, 235-260 (2010).
42. Xia W, Wolfe MS. Intramembrane proteolysis by presenilin and presenilin-like proteases. J. Cell Sci. 116(Pt 14), 2839-2844 (2003).
43. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375(6534), 754-760 (1995).
44. McCarthy JV, Twomey C, Wujek P. Presenil-independent regulated intramembrane proteolysis and gamma-secretase activity. Cell. Mol. Life Sci. 66(9), 1534-1555 (2009).
45. Sisodia SS, St George-Hyslop PH. Gamma-secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3(4), 281-290 (2002).
46. Landman N, Kim TW. Got RIP Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. Cytokine Growth Factor Rev. 15(5), 337-351 (2004).
47. Lemberg MK. Intramembrane proteolysis in regulated protein trafficking. Traffic 12(9), 1109-1118 (2011).
48. Zhang B, Gaiteri C, Bodea LG et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153(3), 707-720 (2013).
49. Thinakaran G, Borchelt DR, Lee MK et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17(1), 181-190 (1996).
50. Laudon H, Winblad B, Naslund J. The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein. Physiol. Behav. 92(1-2), 115-120 (2007).
51. Liu C, Xu P, Lamouille S, Xu J, Derynck R. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol. Cell 35(1), 26-36 (2009).
52. Mu YB, Sundar R, Thakur N et al. TRAF6 ubiquitinates TGF beta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun. 2 (2011).
53. Gudey SK, Sundar R, Mu YB et al. TRAF6 stimulates the tumor-promoting effects of TGF beta type I receptor through polyubiquitination and activation of Presenilin 1. Sci. Signal. 7(307), ra2 (2014).
54. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat. Rev. Mol. Cell Biol. 6(2), 112-126 (2005).
55. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 5(5), 410-421 (2003).
56. Chen YG. Endocytic regulation of TGF-beta signaling. Cell Res. 19(1), 58-70 (2009).
57. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J. Cell. Biol. 158(7), 1239-1249 (2002).
58. Xu P, Liu J, Derynck R. Post-translational regulation of TGF-beta receptor and Smad signaling. FEBS Lett. 586(14), 1871-1884 (2012).
59. Landstrom M. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 42(5), 585-589 (2010).
60. Xu P, Liu J, Sakaki-Yumoto M, Derynck R. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci. Signal. 5(222), ra34 (2012).
61. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 3(8), 600-614 (2002).
62. Schlessinger J, Lemmon MA. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127(1), 45-48 (2006).
63. Carpenter G, Liao HJ. Trafficking of receptor tyrosine kinases to the nucleus. Exp. Cell Res. 315(9), 1556-1566 (2009).
64. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 79C, 34-74 (2013).
65. Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13(5), 328-341 (2013).
66. Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. 15(21), 6484-6489 (2009).
67. Zhang J, Ma W, Tian S et al. RanBPM interacts with TbetaRI, TRAF6 and curbs TGF induced nuclear accumulation of TbetaRI. Cell. Signal. 26(1), 162-172 (2014).
68. Sundvall M, Korhonen A, Vaparanta K et al. Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J. Biol. Chem. 287(27), 23216-23226 (2012).
69. Koch U, Radtke F. Notch signaling in solid tumors. Curr. Topic. Develop. Biol. 92, 411-455 (2010).
70. El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS ONE 8(10), e77433 (2013).
71. Hollmen M, Liu P, Kurppa K et al. Proteolytic processing of ErbB4 in breast cancer. PLoS ONE 7(6), e39413 (2012).
72. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 64(21), 2746-2762 (2007).
73. Chandra M, Zang S, Li H et al. Nuclear translocation of type I transforming growth factor beta receptor confers a novel function in RNA processing. Mol. Cell. Biol. 32(12), 2183-2195 (2012).
74. Hollmen M, Maatta JA, Bald L, Sliwkowski MX, Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 28(10), 1309-1319 (2009).
75. Wu Y, Cain-Hom C, Choy L et al. Therapeutic antibody targeting of individual Notch receptors. Nature 464(7291), 1052-1057 (2010).
76. Sheen YY, Kim MJ, Park SA, Park SY, Nam JS. Targeting the transforming growth factor-beta signaling in cancer therapy. Biomolecules Therapeut. 21(5), 323-331 (2013).
77. Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol. Therapeut. 141(2), 140-149 (2013).
78. Zhou W, Carpenter G. Heregulin-dependent trafficking and cleavage of ErbB-4. J. Biol. Chem. 275(44), 34737-34743 (2000).
79. Ni CY, Murphy MP, Golde TE, Carpenter G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294(5549), 2179-2181 (2001).